Immunic’s (IMUX) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Immunic (NASDAQ:IMUX) in a research report sent to investors on Tuesday morning,Benzinga reports. D. Boral Capital currently has a $17.00 price objective on the stock.

Several other equities research analysts also recently commented on the company. StockNews.com downgraded Immunic from a “hold” rating to a “sell” rating in a report on Monday, November 11th. Leerink Partnrs upgraded shares of Immunic to a “strong-buy” rating in a research note on Monday, September 9th. Leerink Partners restated an “outperform” rating and issued a $5.00 target price on shares of Immunic in a research note on Monday, September 9th. HC Wainwright initiated coverage on shares of Immunic in a report on Monday, November 25th. They set a “buy” rating and a $10.00 price target for the company. Finally, EF Hutton Acquisition Co. I upgraded shares of Immunic to a “strong-buy” rating in a report on Monday, September 16th. One analyst has rated the stock with a sell rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $12.67.

Immunic Trading Up 2.8 %

Shares of NASDAQ IMUX opened at $1.12 on Tuesday. The stock has a fifty day moving average price of $1.14 and a 200 day moving average price of $1.32. Immunic has a 12-month low of $0.97 and a 12-month high of $2.11. The company has a market cap of $100.89 million, a P/E ratio of -0.91 and a beta of 1.88.

Insiders Place Their Bets

In related news, Director Richard Alan Rudick purchased 87,300 shares of Immunic stock in a transaction dated Tuesday, November 12th. The shares were acquired at an average price of $1.15 per share, with a total value of $100,395.00. Following the completion of the transaction, the director now owns 87,300 shares of the company’s stock, valued at approximately $100,395. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.00% of the stock is owned by company insiders.

Institutional Trading of Immunic

Several institutional investors and hedge funds have recently bought and sold shares of IMUX. Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Immunic by 70.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after acquiring an additional 42,383 shares in the last quarter. State Street Corp lifted its stake in Immunic by 7.5% during the third quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after purchasing an additional 11,642 shares during the last quarter. Jane Street Group LLC boosted its holdings in Immunic by 121.4% in the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after purchasing an additional 38,553 shares during the period. Finally, Virtu Financial LLC bought a new stake in Immunic during the third quarter valued at $50,000. Institutional investors and hedge funds own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.